Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed the quarter’s outcomes to growth in the HIV and liver disease businesses, with Biktarvy and Descovy showing strong demand. However, softness in oncology—particularly Trodelvy—and ongoing challenges in the cell therapy segment weighed on overall results. CEO Daniel O’Day acknowledged, “Year-over-year growth in our HIV and liver disease businesses was partially offset by softer than expected Trodelvy sales due to inventory dynamics that masked increase in demand, as well as headwinds in cell therapy.”
GILEAD SCIENCES INC (NASDAQ:GILD) is a quality stock with strong profitability, high ROIC, and reasonable valuation, making it a candidate for long-term investors.
Analysts at Oppenheimer, BMO, Morgan Stanley, and Mizuho weighed in with positive long-term views, though Oppenheimer flagged near-term headwinds tied to court risks and cannibalization of existing products.
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising concerns over global access and equity.
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability and reasonable growth, making it a candidate for value investors. The stock trades below industry averages on key valuation metrics.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of the two agents.
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may have investors wondering how to approach the situation.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 12.9%. This drop was much worse than the S&P 500’s 1.9% loss.
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.
GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors.
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
